Prevention of cardiovascular disease in adult recipients of kidney transplants (Q37945873)

25 August 2017

Prevention of cardiovascular disease in adult recipients of kidney transplants (English)

1 reference

25 August 2017

cardiovascular disease

1 reference

1

Alan G Jardine

1 reference

25 August 2017

Robert S Gaston

2

1 reference

25 August 2017

Bengt C Fellstrom

series ordinal

3

1 reference

25 August 2017

Hallvard Holdaas

series ordinal

4

1 reference

25 August 2017

language of work or name

English

0 references

publication date

1 October 2011

1 reference

25 August 2017

1 reference

25 August 2017

378

1 reference

25 August 2017

1419-1427

1 reference

25 August 2017

9800

1 reference

Premature cardiovascular disease in chronic renal failure

25 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Reduced exposure to calcineurin inhibitors in renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Cardiovascular toxicities of immunosuppressive agents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Predicting coronary heart disease after kidney transplantation: Patient Outcomes in Renal Transplantation (PORT) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Framingham risk score and novel cardiovascular risk factors underpredict major adverse cardiac events in kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Cardiovascular disease medications after renal transplantation: results from the Patient Outcomes in Renal Transplantation study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Reduction in cardiovascular death after kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Renal transplant dysfunction—importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Determinants of left ventricular mass and hypertrophy in hemodialysis patients assessed by cardiac magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Patient survival after renal transplantation III: the effects of statins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Risk for myopathy with statin therapy in high-risk patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Effect of pravastatin on outcomes after cardiac transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Use of cardioprotective medications in kidney transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Hypertension in kidney transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Blood pressure, antihypertensive treatment, and graft survival in kidney transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Improved long-term outcomes after renal transplantation associated with blood pressure control

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: a prospective randomized double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Posttransplantation proteinuria: an approach to diagnosis and management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Diabetes mellitus after kidney transplantation in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Incidence and Cost of New Onset Diabetes Mellitus Among U.S. Wait-Listed and Transplanted Renal Allograft Recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Sirolimus is associated with new-onset diabetes in kidney transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Tacrolimus and posttransplant diabetes mellitus in renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Predictors of new onset diabetes after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Alcohol Consumption, New Onset of Diabetes After Transplantation, and All-Cause Mortality in Renal Transplant Recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

TCF7L2 polymorphism associates with new-onset diabetes after transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Abnormal glucose metabolism and metabolic syndrome in non-diabetic kidney transplant recipients early after transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Guidelines for the treatment and management of new-onset diabetes after transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Inflammation in renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

High pretransplant parathyroid hormone levels increase the risk for graft failure after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Prognostic associations of serum calcium, phosphate and calcium phosphate concentration product with outcomes in kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Anemia, renal transplantation, and the anemia paradox

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Effects of single-nucleotide polymorphisms in MTHFR and MTRR on mortality and allograft loss in kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Management of cytomegalovirus infection in solid organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Revisiting the effects of CMV on long-term transplant outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

Cardioprotective medication use after acute myocardial infarction in kidney transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961334-2

7 January 2021

10.1016/S0140-6736(11)61334-2

Identifiers

DOI

1 reference

25 August 2017

1 reference